NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ACT-GLOBAL Adaptive Platform Trial for Stroke

RecruitingPhase 3

Sponsor: The George Institute

Conditions: Stroke

Interventions: Standard-dose intravenous tenecteplase, Low-dose intravenous tenecteplase, No intravenous tenecteplase, Conservative Blood Pressure Control, Moderate Blood Pressure Control

Countries: Australia, Canada

Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Platform Inclusion Criteria:

1. Age ≥18 years
2. Clinical diagnosis of stroke

Platform Exclusion Criteria:

There are no platform level exclusion criteria

Each state and domain will specify additional inclusion and exclusion criteria in the respective Domain-Specific Registration. Patients who fulfill the overall platform criteria will be assessed for enrollment into each active domain.

Locations (2)

Sydney, New South Wales, Australia
Calgary, Alberta, Canada